Compare Johnson & Johnson (JNJ) vs Noble Corporation plc (NE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Noble Corporation plc — how do they compare? Johnson & Johnson trades at $249.45 (market cap $598.96B), while Noble Corporation plc trades at $42.35 (market cap $6.48B). The key difference: Johnson & Johnson is far larger — about 92.4× Noble Corporation plc's market cap, and Noble Corporation plc pays the higher dividend (4.93%). Which is the better fit depends on your goals.
| JNJ | NE | |
|---|---|---|
Market Cap | $598.96B | $6.48B |
Volume | 6,156,228 | — |
Sector | Health | Technology |
52-Week High | $267.24 | $54.37 |
52-Week Low | $164.36 | $25.70 |
Enterprise Value | $631.90B | $7.73B |
Dividend Yield | 2.15% | 4.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
Noble Corporation (NE) trades at $40.60, down 2.17% today, with mixed technical signals showing a bullish moving average trend but bearish oscillators. The company maintains solid fundamentals with a $3.29B revenue in 2025 and a net income margin of 7.17%, supported by recent contract wins like the $136.2M Brunei drilling deal. Cash flow remains positive, and a $0.50 dividend was recently declared, payable in June 2026.
The outlook is cautiously optimistic with a consensus price target of $49.75 offering 22.5% upside, though recent earnings misses and competitive pressures in offshore drilling pose risks. Analyst sentiment is divided with 31% buy ratings, reflecting confidence in Noble's high-specification rig fleet and contract backlog, balanced by execution challenges and oil price volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →
